Fibrosis company Avalyn seeks NASDAQ listing amid volatility: Finance Report

The robust IPO queue some had hoped for in early 2026 hasn’t materialized. But one biotech, following a relatively de-risked path, filed for a NASDAQ listing this week despite the market’s instability.

Avalyn Pharma Inc., a Boston-based developer of inhaled therapeutics for pulmonary fibrosis, filed a prospectus late Wednesday. The company has two programs in Phase II testing: AP01, an inhaled version of pirfenidone in the Phase IIb MIST trial to treat progressive pulmonary fibrosis; and AP02, a formulation of nintedanib in the Phase II AURA trial to treat idiopathic pulmonary fibrosis...